Dyne Therapeutics, Inc.
NASDAQDyne Therapeutics enters its June 5 earnings call with short sellers adding quietly and the stock down 7.5% on the day — a pre-results setup that concentrates attention on what clinical data or guidance shifts might move the needle. The short position has been creeping higher for weeks. Short interest as a percentage of free float hit 13.4% on June 2, up from roughly 12.6% a month…
Snapshot as of 5 Jul 2026
Dyne Therapeutics enters its June 5 earnings call with short sellers adding quietly and the stock down 7.5% on the day — a pre-results setup that concentrates attention on what clinical data or guidance shifts might…
Dyne Therapeutics fell 13% on the week to $15.92 — yet options traders are suddenly the most bullish they've been all year. The options signal is the sharpest thing in this week's data. The put/call ratio collapsed to…
DYN posted a better-than-expected Q1 this week, and the 5.2% weekly gain shows investors noticed. The real question now is whether a narrowing loss and a fresh analyst nudge from Bernstein are enough to dent a short…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for DYN — free to start on ORTEX.
Sign up for free →Open DYN on ORTEX